369 related articles for article (PubMed ID: 35312963)
1. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
Hashimoto H; Tanaka Y; Murata M; Ito T
Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
[TBL] [Abstract][Full Text] [Related]
2. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
3. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
Wong JL; Rosenberg JE
Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
[TBL] [Abstract][Full Text] [Related]
4. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
5. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Mantia CM; Sonpavde G
Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
[TBL] [Abstract][Full Text] [Related]
6. Enfortumab vedotin to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
[TBL] [Abstract][Full Text] [Related]
7. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
McGregor BA; Sonpavde G
Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
[No Abstract] [Full Text] [Related]
8. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
12. Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
Bouleftour W; Sargos P; Magne N
Curr Oncol Rep; 2023 Mar; 25(3):181-188. PubMed ID: 36696077
[TBL] [Abstract][Full Text] [Related]
13. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
Heath EI; Rosenberg JE
Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
[TBL] [Abstract][Full Text] [Related]
14. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
15. New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?
Hoffman-Censits J; Lombardo K; McConkey D; Hahn NM; Bashir B; Kelly WK; Johnson B; Matoso A
Urol Oncol; 2021 Oct; 39(10):619-622. PubMed ID: 34148797
[TBL] [Abstract][Full Text] [Related]
16. Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G
Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
[TBL] [Abstract][Full Text] [Related]
19. Enfortumab vedotin - next game-changer in urothelial cancer.
Maas M; Stühler V; Walz S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Jul; 21(7):801-809. PubMed ID: 33325754
[No Abstract] [Full Text] [Related]
20. Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.
Fahey CC; Nebhan CA; York S; Davis NB; Hurley PJ; Gordetsky JB; Schaffer KR
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]